Lucid Diagnostics Inc.
LUCD
$1.39
$0.118.59%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 179.27% | 379.19% | 370.50% | 544.03% | 165.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 179.27% | 379.19% | 370.50% | 544.03% | 165.49% |
| Cost of Revenue | 4.43% | 3.75% | 37.41% | 65.46% | 152.01% |
| Gross Profit | 52.10% | 52.02% | 16.08% | -9.70% | -147.94% |
| SG&A Expenses | -5.86% | -12.60% | -21.14% | -10.63% | 1.55% |
| Depreciation & Amortization | -53.10% | -31.54% | -16.04% | 12.49% | 62.15% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.82% | -13.70% | -18.65% | -10.10% | 0.79% |
| Operating Income | 13.22% | 19.34% | 22.88% | 13.81% | 0.98% |
| Income Before Tax | 21.05% | 18.01% | 21.81% | 6.24% | -8.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.05% | 18.01% | 21.81% | 6.24% | -8.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.05% | 18.01% | 21.81% | 6.24% | -8.02% |
| EBIT | 13.22% | 19.34% | 22.88% | 13.81% | 0.98% |
| EBITDA | 12.04% | 19.35% | 23.67% | 15.34% | 3.27% |
| EPS Basic | 19.58% | 16.17% | 20.60% | 18.55% | 4.65% |
| Normalized Basic EPS | 26.82% | 30.77% | 33.36% | 23.22% | 10.43% |
| EPS Diluted | 19.58% | 16.17% | 20.60% | 18.55% | 4.65% |
| Normalized Diluted EPS | 26.82% | 30.77% | 33.36% | 23.22% | 10.43% |
| Average Basic Shares Outstanding | 14.75% | 13.31% | 13.64% | 15.44% | 13.96% |
| Average Diluted Shares Outstanding | 14.75% | 13.31% | 13.64% | 15.44% | 13.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
